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Kallikrein 6 (hK6, also known as protease M/zyme/neurosin) is a member of the human kallikrein gene family. We have previously
cloned the cDNA for this gene by differential display and shown the overexpression of the mRNA in breast and ovarian primary
tumour tissues and cell lines. To thoroughly characterise the expression of this kallikrein in ovarian cancer, we have developed a novel
monoclonal antibody specific to hK6 and employed it in immunohistochemistry with a wide range of ovarian tumour samples. The
expression was found elevated in 67 of 80 cases of ovarian tumour samples and there was a significant difference in the expression
levels between normal and benign ovarian tissues and the borderline and invasive tumours (Po0.001). There was no difference of
expression level between different subtypes of tumours. More significantly, high level of kallikrein 6 expression was found in many
early-stage and low-grade tumours, and elevated hK6 proteins were found in benign epithelia coexisting with borderline and invasive
tissues, suggesting that overexpression of hK6 is an early phenomenon in the development of ovarian cancer. Quantitative real-time
reverse transcription–polymerase chain reactions also showed elevated kallikrein 6 mRNA expression in ovarian tumours. Genomic
Southern analysis of 19 ovarian tumour samples suggested that gene amplification is one mechanism for the overexpression of hK6 in
ovarian cancer.
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Ovarian cancer is the fourth most common form of cancer in
females in the United States and accounts for more than half of the
deaths due to gynaecological malignancy (Ozols, 2002). Ovarian
cancer of epithelial origin, which constitutes more than 90% of the
disease, is the most lethal among all gynaecological malignancies,
with a 5-year survival rate of only 20% (Bast et al, 1990, pp 265–
275; Taylor and Schwartz, 1994; Schwartz and Taylor, 1995). The
poor prognosis is mainly due to the lack of symptoms at the early
stage of disease. At the time of diagnosis about 70% of patients
have cancer cells already spread to the pelvic and abdominal
viscera or developed distant metastasis (Stage III/IV) and are
rarely curable. In contrast, the survival rate will exceed 90% at 5
years if the disease is detected in Stage I, when tumours are
confined to the ovaries (Junor et al, 1994). Therefore, early
detection and early intervention is critical to improve the clinical
outcome of ovarian cancer patients.
Ovarian carcinogenesis is believed to be a multistep process. To
investigate the features of the earliest form of ovarian carcinoma,
extensive pathological studies of grossly normal ovarian samples
have revealed that high-grade serous ovarian carcinomas might
develop de novo from surface epithelium and its inclusions, as well
as from endosalpingeal tissues in the cortical stroma (Ryuko et al,
1992; Bell and Scully, 1994). The coexistence of cytologically
benign, borderline and malignant epithelium in some ovarian
carcinomas and evidence of areas of histologic transition from
benign to borderline or to malignant epithelium support
the contention that many low-grade ovarian carcinomas, particu-
larly those of the mucinous type, may arise from pre-existing
benign or borderline lesions (Powell et al, 1992; Scully et al,
1992, pp 139–144). Despite these pathological findings, the
molecular basis for the pathogenesis of epithelial ovarian
tumours is largely unknown. Discovery of biomarkers that are
present early in the abnormal endosalpingeal tissues or in
benign or borderline lesions coexisting with malignant
carcinomas may further our understanding of the mechanism of
early ovarian carcinogenesis.
We have previously identified by differential display a cDNA
sequence that is highly expressed in primary breast and ovarian
tumour tissues and cell lines (Anisowicz et al, 1996). The encoded
protein, which originally was named as protease M, shows strong
homology to the human kallikrein (hK) family proteins (for a
review see Schachter, 1980; Yousef and Diamandis, 2001) and has a
revised nomenclature of kallikrein 6 (KLK6 for the gene and hK6
for the encoded protein). There are at least 15 human kallikrein
genes that are co-localised as a cluster within a 300-kb region at
chromosome 19q13.3–13.4. They also share significant similar
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amino-acid levels (Yousef and Diamandis, 2001). All genes encode
for putative serine proteases with conserved signal peptide
sequence for secretion and catalytic triad residues in the
appropriate positions. Of them, kallikrein 3 (hK3), or more
commonly named as prostate-specific antigen (PSA), has gained
prominence as the most valuable tumour marker and is currently
used widely for the diagnosis, monitoring, and population
screening for prostate cancer (Catalona et al, 1991; Mettlin et al,
1993). hK3 has also been reported to cleave insulin-like growth
factor-binding protein-3, resulting in increased availability of
insulin-like growth factor. This suggests that hK3 enzymatic
activity may promote proliferation, migration, and metastasis of
prostate cancer cells (Cohen et al, 1992). It will be of interest to
determine the functions and the potential of serum biomarker
development for the other members of the kallikrein family.
Indeed, recent studies have shown that the expression of many
kallikreins including hK4, hK5, hK6, hK7, and hK8 has emerged as
being related to breast, ovarian, and other human cancers
(Underwood et al, 1999; Diamandis et al, 2000; Kim et al, 2001;
Yousef et al, 2003). Further studies of these kallikreins in ovarian
cancer and the development of detection tools may facilitate better
understanding of this family of proteases in ovarian cancer and
improve the prognosis of ovarian cancer patients.
In order to characterise the expression pattern of hK6 in
different subtypes and stages of ovarian tumour tissues and to
develop a tool for the potential use of measuring hK6 levels in
patient serum, we have established a novel monoclonal antibody
that has high specificity and reactivity to hK6. Here we report the
utility of this monoclonal antibody in determining the expression
pattern of different subtypes and stages of ovarian tumour tissues.
In conjunction with the data of mRNA expression, we found that
hK6 is highly expressed in various subtypes of ovarian tumour
tissues, and is also present in early-stage tumours. We also
observed high expression of hK6 in the apparently benign epithelia
coexisting with borderline and invasive tumours in some samples.
The elevated expression of hK6 in early-stage and low-grade
ovarian tumours may suggest that upregulation of this protein may
be an early event during ovarian cancer development and hK6 may
have potential use as biomarkers for the early detection of ovarian
cancer. The presence of high-quality monoclonal antibodies will be
beneficial for the development of a standard screening method for
large-scale population screening. We have also performed genomic
Southern analysis to determine if gene amplification is one
mechanism for the overexpression of hK6 in ovarian tumours.
MATERIALS AND METHODS
Biologic specimens
All patient-derived biologic specimens were collected and archived
under protocols approved by the Human Subjects Committee of
the Brigham and Women’s Hospital, Boston, MA, USA. Ovarian
tissues and cells were freshly collected from women undergoing
surgery at the Brigham and Women’s Hospital for a diagnosis of
primary ovarian cancer or from control subjects having hyster-
ectomy and oophorectomy for benign disease. All tumour tissues
were collected from the primary ovarian sites and were confirmed
histologically. Cultures of normal human ovarian surface epithelial
(HOSE) cells were established by scraping the surface of the ovary
and growing the recovered cells in a mixture of medium 199 and
MCDB105 medium supplemented with 10% fetal calf serum (Sigma
Chemical Co., St. Louis, MO, USA) as described previously (Tsao
et al, 1995). For fresh-frozen sections, fresh specimens were
embedded in Tissue Tek OCT medium (Miles, Inc., Indianna,
USA), snap-frozen in liquid nitrogen, and stored at  801C until
use.
Isolation of monoclonal antibodies specific to hK6
cDNA for hK6 was amplified using RT–PCR reaction with the
primers 50-CTGGAATTCTTGGTGCATGGCGGACCC-30 and 50-
CTGTCTAGATCACTTGGCCTGAATGGTTTT-30. The fragment
was restricted with EcoRI and XbaI and subcloned into the
pMAL-c2X vector DNA (New England BioLabs, Beverly, MA, USA)
that has been restricted with the same enzymes. The resulting
construct was transformed into the Escherichia coli strain TB1.
The procedures for the induction of maltose-binding protein
(MBP)-hK6 recombinant fusion protein synthesis by isopropyl
thiogalactoside (IPTG), preparation of crude extracts, and the
purification of the recombinant protein over the amylose resin
column were according to the manufacturer’s recommendation.
Kallikrein 6 protein was released from the fusion protein by Factor
Xa digestion and purified by SDS–polyacrylamide gel electro-
phoresis. The antigen was injected into five female Balb/c mice in a
series of three injections given at 3-week intervals. The first
consisted of 75mg per mouse in Freunds complete adjuvant, while
the second and third injections were 50mg per mouse in
incomplete Freunds adjuvant. Mice were boosted with 50mgo f
protein 4 days prior to fusion.
The spleen cells were fused with NS-1/Ag3 myeloma cells using
polyethylene glycol, and plated out in HAT-selective growth
medium. After 10 days, supernatants from each well were assayed
by enzyme-linked immunosorbent assay (ELISA) and colonies
showing reactivity were also tested by Western blotting. Specific
antibody-secreting hybridomas were picked and transferred to
separate wells in a 24-well plate and the specificity was further
confirmed by ELISA and Western blotting. Positive lines were
subsequently cloned by double-dilution and reassayed. Positive
clones were expanded and the IgG subclasses were determined by
ImmunoPure isotyping kit from Pierce.
In situ immunohistochemistry
For in situ immunohistochemistry, 7mM sections were cut from the
paraffin archived tissues and mounted on Superfrost/Plus micro-
scopic slides (Fisher Scientific, Pittsburgh, PA, USA), and
incubated at 501C overnight. They were deparaffinised in xylene
and rehydrated in graded ethanol. For antigen unmasking, sections
were immersed in antigen unmasking solution (Vector Lab, Inc.,
Burlingame, CA, USA) and boiled in microwave oven for 10min.
The tissues sections were then washed in phosphate-buffered
saline (PBS) and quenched in 0.2% H2O2 for 20min. The sections
were washed in PBS for 20min, incubated with normal horse
blocking serum for 20min, and subsequently incubated overnight
with anti-hK6 antibody. After incubation, the sections were washed
in PBS for 10min, incubated with diluted biotinylated secondary
horse anti-mouse antibody for 30min, and washed again in PBS
for 10min. After washing, the sections were incubated with
VECTASTAIN Elite ABC reagent (Vector Inc.) for 30min, washed
in PBS for 10min, incubated in diaminobenzidine (DAB) solution
for 5min, and washed in water for 10min. The sections were
counterstained with haematoxylin, dehydrated with an ascending
series of alcohol, cleared in xylene, and mounted in Permount
(Fisher Scientific). The specificity of the staining was confirmed by
preabsorbing the antibody with the purified hK6 protein for 2h at
371C before applying to the sections. The results of immunohis-
tochemistry were quantified using a semiquantitative scoring
system (Yiu et al, 2001). The weighted score is obtained by
multiplying the staining intensity score (3þ, strong positive stain
in most cells; 2þ, moderate stain in cells; 1þ, weak stain in cells;
0, no evidence of stain) and score for the percentage of positive
cells (3þ, most of cells stained; 2þ, half of cells stained; 1þ, few
cells stained; 0, no cells stained). Representative photmicrographs
were recorded by a digital camera (Optronic, Inc., Muskogee, OK,
USA).
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yLaser capture microdissection
Tissues stored in Tissue Tek OCT medium at  801C were
sectioned at 7mM in a cryostat (Leica, Inc., Northvale, NJ, USA).
Sections were mounted on uncoated glass slides and immediately
fixed in 70 and 50% ethanol for 30s each, stained with
haematoxylin–eosin, dehydrated in alcohol solution of increasing
concentration, and cleared in xylene for 5min. After being air-
dried for 3min, the sections were laser microdissected using the
PixCell II apparatus (Arcturus, Inc., Mountain View, CA, USA).
Quantitative real-time reverse transcription–polymerase
chain reaction
Quantitative real-time reverse transcription–polymerase chain
reaction (qRT–PCR) was used to quantify the mRNA levels of
kallikrein 6 in the tissue samples. Frozen tumour tissues were
pulverised on dry ice and total RNA was isolated using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA). For LCM dissected
materials, RNA was extracted using a StrataPrep Total RNA
miniprep kit (Stratagene, La Jolla, CA, USA). cDNA synthesis was
performed with 50ng of RNA samples using the TaqMan reverse
transcription reagent kit (Perkin-Elmer, Wellesley, MA, USA), and
quantitative PCR reactions were performed using an SYBR Green I
kit, which contained 2ml of cDNA, 1  SYBR PCR buffer, 3mM
MgCl2, 0.8mM dNTP, and 0.025Uml
 1 AmpliTaq Gold (PE Applied
Biosystems, Inc., Framingham, MA, USA). Real-time PCR primers
for kallikrein 6 (forward primer: 50-TCCTTCCCCCGACTCAA
GAAT-30; reverse primer: 50-TCCGCCATGCACCAACTTA-30) were
designed using the PrimerExpress software (Perkin Elmer).
Another PCR reaction using a set of primers for the housekeeping
gene, cyclophillin A, was used to normalise for variances in input
cDNA. The reactions were performed in an ABI PRISM 5700
Sequence Detector (PE Applied Biosystems, Inc.) with denatura-
tion for 10min at 951C followed by 40 PCR cycles of denaturation
at 951C for 15s and annealing/extension at 601C for 1min. The
threshold cycle (CT) value for each reaction, reflecting the number
of PCR cycles needed to give exponential amplification of
kallikrein 6 amplicon, and the relative level of kallikrein 6 for
each sample was calculated as described (Huang et al, 2002). At
least duplicated PCR reactions were performed and the values
averaged for each sample.
Statistical analysis
All analyses were performed using MINITAB version 13 (MINITAB
Inc.). One-way ANOVA is adopted to test whether the mean
kallikrein 6 expression levels vary depending on the subtype,
diagnosis, grade, and stage respectively. The relative measures of
kallikrein 6 mRNA level were compared using log-tranformed
values. When an overall F-test was significant in the ANOVA,
Fisher’s pairwise comparisons were used to compare the mean
kallikrein 6 levels among groups.
Establishment of SKOV3 cells that overexpress hK6 and
immunostaining
Full-length cDNA encoding kallikrein 6 was produced by reverse
transcription polymerase chain reaction using the primer set
(Forward primer: 50-GGCGGACAAAGCCCGATTGTTCC-30, re-
verse primer: 50-GATCTCGAGTCAATCGTGATGGTGATGGT
GATGCTTGGCCTGAATGGTTTTTTGGATCC-30). The PCR pro-
duct was first cloned into the TOPO TA cloning vector, pCRII-
TOPO (Invitrogen). The cDNA was then restricted from the vector
by EcoRI and NotI digestion and cloned into Invitrogen T-REx
mammalian inducible vector pcDNA6/TO/mycHis A at EcoRI and
NotI sites. The resulting construct was transfected into an SKOV3
cell line that also expresses regulator protein TetR from an
integrated plasmid, pcDNA6/TR (Invitrogen). Positive sublines
were selected using antibiotics blasticidin and zeocin as described
in the manufacturer0s protocol. For immunstaining, the SKOV3
cell line that harboring the hK6-expressing construct was induced
in the presence of 1mM of tetracycline, while the control is the same
cell line treated with the solvent vehicle. These together with OVCA
429 and the immortalised HOSE cell line were fixed by adding 4%
paraformaldehyde. The fixed cells were washed twice in PBS for
20min, permeabilised in 0.2% Triton X-100 in PBS, washed again,
incubated with normal horse blocking serum for 20min, and
subsequently incubated with anti-hK6 antibody at room tempera-
ture for 1h. After incubation, the cells were washed in PBS for
10min, incubated with diluted biotinylated secondary horse anti-
mouse antibody for 30min, and washed again in PBS for 10min.
After washing, colour development was performed using the
VECTASTAIN Elite ABC Kit (Vector Inc.) as described above.
Genomic Southern analysis
Frozen tumour tissues were pulverised on dry ice and genomic
DNA was isolated according to the standard protocol (Ausubel
et al, 1988). For Southern blot analysis, 5mg of genomic DNA was
restriction digested with BamHI and electrophoretically resolved
on a 1% agarose gel. The genomic DNA was denatured and
neutralised, transferred onto nylon membrane (Amersham, Piscat-
away, NJ, USA) according to the manufacturer’s recommendation.
Full-length kallikrein 6 cDNA was labelled with a-[
32P]dCTP using
the multiprime labelling kit (Roche Molecular Diagnostics,
Indianapolis, IN, USA) and hybridised to the membrane using
the standard protocol (Ausubel et al, 1988). Genomic DNA
extracted from normal HOSE primary cultures was used as
control. Stringent hybridisation and wash conditions were
employed to ensure no cross-hybridisation of the probe to other
kallikrein genes. Hybridisation signals were detected by auto-
radiography and quantified by a Bio-Rad BGS-700 densitometer.
Quantitative real-time polymerase chain reaction for
genomic DNA
Quantitative real-time polymerase chain reaction (qPCR) was used
to quantify the gene copy number of kallikrein 6 gene for the tissue
samples. In total, 10ng of tissue genomic DNA and two kallikrein 6
primer sets (50-end primer set: 50-ACCCTCCAGCCCATACCAAC
30 and 50-ACATGGGAAACCACAGGCA-30; and 30-end primer set:
50-GGACGCAAAGAAAGGGCAG-30 and 50-CCACCTCGTGTCTT
GAGGACA-30) were used in the genomic qPCR reactions.
Quantitative PCR reactions were performed using an SYBR Green
I kit as mentioned for qRT–PCR. Primer sets for two single-copy
genes, phosphatidylserine decarboxylase (50-AGCAGAGCCACA
CAGCCTTC-30 and 50-GGTGAATGTGGGAACGGAAA-30) and
DNA topoisomerase II beta (50-CCTCATCCTTAGAGGCCCCA-30
and 50-GAGACCTAACCGGGAATCCG-30) were used to normalise
the input DNA for different samples.
RESULTS
Isolation and characterisation of monoclonal antibodies
specific to kallikrein 6
In order to generate specific antibody for hK6, full-length cDNA
for KLK6 gene was cloned into (MBP) encoding pMAL-c2X vector
as described in Materials and Methods. Fusion proteins were
purified from the lysates of transformed E. coli. The hK6 protein
was released from the fusion by Factor Xa digestion and used in
the immunisation of mice. Spleen cells harvested from one of the
immunised mouse were fused with the myeloma cell line NS-1/
Ag3. After screening for more than 1000 clones, one of the clones,
2D4, showed very high reactivity and specificity to hK6 protein.
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such as hK1 and hK3 (data not shown). As shown in Figure 1, the
antibody stained positively the cytoplasm of an SKOV3 cell line
that was induced to express hK6 by tetracycline (Figure 1A) but
not in the uninduced cells (Figure 1B). The antibody also
recognised the endogenous hK6 proteins present in the OVCA429
cell line (Figure 1C). The immortalised normal HOSE cells only
stained negatively in the assay (Figure 1D). The IgG subclass of
2D4 was determined to be IgG2b by ImmunoPure isotyping kit
from Pierce.
Characterisation of hK6 expression in normal and tumour
ovarian tissues
We employed 2D4 in immunohistochemical studies to determine
the expression levels of hK6 in paraffin block sections of three
normal ovarian tissues, nine benign tissues, 18 borderline and 62
invasive ovarian tumours. The mean immunostaining scores in
tissue sections from healthy ovary, benign ovarian tumour,
borderline ovarian tumour, and invasive ovarian cancer were 0.0,
1.83, 3.42, and 3.71, respectively (Table 1). The overall F-test for
the diagnostic groups was statistically significant (Po0.001),
indicating that mean immunostaining scores varies between
diagnostic groups. The Fisher’s pairwise comparison procedure
was employed to compare the mean immunostaining scores at 5%
level. The result shows that the healthy and benign tumours have
significantly lower scores than the borderline and invasive
tumours. Within the cancer (borderline and invasive) groups,
there was no significant difference among histologic groups, as
well as among different grades and stages (Table 1). Figures 1(E
through J) show representative results of the hK6 staining in
normal ovarian epithelium, stage I and stage III serous tumours, as
Figure 1 Use of monoclonal antibody 2D4 in immunostaining and immunohistochemistry. Immunostaining of (A) tetracycline-induced hK6 in SKOV3 cell
line; (B) the same cell line without tetracycline induction; (C) OVCA429 ovarian carcinoma cell line; (D) immortalised normal HOSE cells.
Immunohistochemical staining for hK6 in (E) normal ovary; (F) endometrioid; (G) mucinous; (H) stage I clear cell; (I) stage I serous; and (J) stage III serous
ovarian tumour tissues. Immunopositive cells were stained brown in the cytoplasm. To highlight the tumour cells, the slides were counterstained with
haematoxylin (purple).
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tumour tissues. While there was no positive staining for the
normal ovarian epithelial and stroma cells, hK6 immunoreactivity
was observed in the cellular membrane and cytoplasm of tumour
cells in the cancer groups.
In particular, we observed that in some mucinous tumour
samples, there was strong hK6 staining in some apparently benign
epithelia similar to the coexisting borderline tumours (Figure 2A),
or in borderline tumours coexisting with invasive tumours
(Figure 2B). As it is believed that mucinous ovarian carcinomas
may arise from pre-existing benign or borderline lesions, it is very
likely that elevated hK6 expression coincides with the early stages
of ovarian cancer development.
Besides the evaluation of protein expression, we also determined
kallikrein 6 mRNA levels between healthy human HOSE primary
cell cultures and borderline and invasive tumours. For the
borderline and invasive tumour samples other than serous
subtype, tumour cells were microdissected from frozen sections
by Laser Capture Microdissection (LCM) and total RNA was
extracted from the captured tumour cells. The results in Table 2
confirmed the significant differences in kallikrein 6mRNA
expression between normal HOSE primary cell cultures and
tumour tissues (Po0.001). For comparisons between different
subtypes of tumours, the F-test in the ANOVA was marginally
significant (P¼0.054), indicating that the mean expression levels
were not the same for different subtypes of tumours. The result of
the Fisher’s pairwise comparison further indicated that mixed
tumours had significantly lower mRNA expression levels than
other types of tumours. It can be seen from Table 2 that the mean
Table 1 Expression of hK6 in relation to histopathologic characteristics
by immunohistochemical analysis
Characteristics
No. of
patients
Mean of
scores P-value
All patients 92 3.35
Diagnostic category
Healthy 3 0.00 o0.001
Benign 9 1.83
Borderline 18 3.42
Invasive 62 3.71
Histology of cancer
Serous 44 3.44 0.205
Mucinous 16 3.94
Endometrioid 9 3.11
Clear Cell 4 5.00
Mixed 7 4.14
Tumour differentiation
Borderline 18 3.42 0.792
Grade 1 23 3.46
Grade 2 7 4.07
Grade 3 29 3.64
Stage
I 24 3.48 0.965
II 11 3.36
III 31 3.61
IV 5 3.70
Figure 2 Elevated expression of hK6 in benign and borderline lesions of mucinous ovarian tumours. Positive 2D4 staining in immunohistochemistry of (A)
a mucinous case, showing both single stratified layer of benign (BN) epithelium and borderline (BOT) tumour component with pleomorphism; (B)a
mucinous tumour showing positive 2D4 staining in both borderline (BOT) cells and invasive (INV) tumour components.
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various stages and grades of borderline and invasive tumour
samples.
Characterisation of kallikrein 6 gene copy number in
ovarian carcinomas
In order to determine if gene amplification is one mechanism in
causing elevated hK6 expression, we have performed genomic
Southern analysis for 19 ovarian carcinoma samples. The results
are presented in Figure 3. Four out of 19 ovarian carcinomas
exhibited higher copy number of kallikrein 6 gene. We also
performed quantitative real-time PCR with the genomic DNA
samples and the results were consistent with those of the genomic
Southern analysis (Figure 3).
DISCUSSION
As most ovarian cancer patients are diagnosed only at a late stage
and have a dismal overall survival rate, there is a paramount need
for better early detection methods. Although a number of tumour
markers have been identified (Bast et al, 1987; Berek and Bast,
1995; Mackey and Creasman, 1995; Chen and Karlan, 1998), a
useful screening marker for ovarian cancer has not yet been clearly
established. The most widely used marker, CA125, has shown
merit in pilot screening studies and ovarian cancer management,
but the sensitivity for early-stage disease before clinical detection
remains questionable (Bast et al, 1998).
We have previously identified by differential display a cDNA
that is highly expressed in ovarian tumour (Anisowicz et al, 1996).
Sequence analysis has shown that this novel protein belongs to the
human kallikrein protein family. One member of the kallikrein
family, prostate-specific antigen (PSA), has been successfully used
in the diagnosis and clinical management of prostate cancer
(Catalona et al, 1991; Mettlin et al, 1993). The high expression of
hK6 in ovarian tumour cells and its secretory nature suggests that
this kallikrein may have potential as a novel biomarker for ovarian
cancer detection. To develop a useful screening tool and to
examine the clinical relevance of hK6, we have developed a novel
monoclonal antibody that has high specificity and reactivity to
hK6. This antibody does not react with other kallikrein members
and it may be very valuable in evaluating the clinical potential
of hK6.
The employment of the monoclonal antibody in immunohis-
tochemistry of archived ovarian paraffin sections has shown the
significant overexpression of hK6 proteins in ovarian tumour cells
compared with normal ovarian epithelium and benign diseases.
There was no significant difference in hK6 expression among
different subtypes, grades, and stages of ovarian cancer groups.
However, we saw a slightly higher proportion of clear cell samples
that overexpress hK6 (Table 1). High expression of hK6 was also
observed in the borderline and early-stage invasive samples. In
particular, we observed that in some mucinous tumour samples,
there was strong hK6 staining in some apparently benign epithelia
similar to the coexisting borderline tumours (Figure 2A), or in
borderline tumours coexisting with invasive tumours (Figure 2B).
As it is believed that mucinous ovarian carcinomas may arise from
pre-existing benign or borderline lesions (Powell et al, 1992; Scully
et al, 1992, pp 139–144), upregulation of hK6 expression may be
an early event of cancer development and hK6 may have potential
as a novel biomarker for early detection of ovarian cancer. In
addition, mRNA levels were mostly consistent with the protein
levels, suggesting that transcriptional regulation may be a
mechanism that regulates the expression of hK6. Interestingly,
many of the kallikrein genes are coregulated by steroid hormones
(Young et al, 1995), and recent analysis of the genomic sequence of
the kallikrein gene cluster has identified a minisatellite element
that is present only in this region of chromosome 19 (Yousef et al,
2001). Studies of the significance of this element and other
potential sequences that regulate the expression of kallikrein genes
may reveal the early events of kallikrein upregulation, particularly
in relation to ovarian cancer development. Nevertheless, our
genomic Southern analysis and genomic quantitative real-time
PCR data have indicated amplification of kallikrein 6 gene in some
Table 2 Human kallikrein 6 mRNA expression in ovarian tissues
Characteristics No. of patients Mean of expression P value
All patients 59 3.61
Diagnostic category
Healthy 7  0.76
Borderline 5 4.48 o0.001
Invasive 46 4.05
Histology of cancer
Serous 35 4.61
Mucinous 6 3.00
Endometrioid 5 4.67 0.054
Clear cell 2 4.42
Mixed 4 1.64
Tumour differentiation
Borderline 4 4.78
Grade 1 5 4.04
Grade 2 9 3.62 0.819
Grade 3 33 4.26
Stage
I 10 4.21
II 4 3.16
III 28 4.26 0.757
IV 7 3.66
Expression is determined by quantitative real-time reverse transcription–PCR. For
statistical analysis, natural logarithm was taken for the expression levels of KLK6 in
tumour cells relative to normal HOSE cells.
Figure 3 Genomic Southern analysis and quantitative real-time PCR of tumour DNA. Equal amounts of 19 tumour DNA were restricted with BamHI and
electrophoresed on an agarose gel and Southern blot analysis was performed using the KLK6 cDNA probe. The 5- and 3.2-kb bands of the KLK6 gene are
marked by arrows. Genomic DNA of a normal ovarian epithelial primary culture (HOSE) was used as control. Results of the quantitative real-time PCR of
the tumour samples relative to the normal HOSE cells are shown at the bottom.
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rearranged in many human solid tumours including pancreatic
carcinomas, astrocytomas, thyroid tumours, and ovarian cancers
(Mitelman, 1994, pp 3067–3198), gene amplification is likely
another mechanism for the elevated expression of hK6 in ovarian
tumours.
The functional roles of kallikrein 6 and many other kallikreins
have not yet been established. As they are secreted serine
proteases, their actions through the degradation of the extra-
cellular matrix may facilitate tumour cell spread. Alternatively,
they may be part of an enzymatic cascade pathway that involves
enzyme activation followed by proteolysis (Matrisian, 1999). The
establishment of functional recombinant proteins and kallikrein-
expressing cell lines will facilitate functional studies and provide
information about the possible roles of these kallikreins in
aberrant cell growth and cell invasion.
In summary, we have developed a novel monoclonal antibody to
confirm the high expression levels of hK6 in ovarian tumour cells
than in normal ovarian epithelial cells. High expression of hK6
protein in coexisting benign, borderline and invasive ovarian
tumours was observed. The examined tumours also expressed high
levels of kallikrein 6 mRNA. Southern blot and quantitative real-
time PCR using genomic DNA suggested that gene amplification is
one mechanism for the high expression of kallikrein 6 in ovarian
tumours. The development of high-quality monoclonal antibodies
facilitates the evaluation of biomarkers and allows further screen-
ing tool development for early detection of ovarian cancer.
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